Eli Lilly Inks Multibillion-Dollar Pact to Develop Precision Cancer Therapies
Eli Lilly partners with Stipple Bio in a $5.9B licensing deal to develop targeted cancer treatments using its Pointillist Platform.
Follow the latest Eli Lilly & Co. (LLY) news and market headlines alongside the live LLY price. Stay informed on what's moving LLY.
Eli Lilly partners with Stipple Bio in a $5.9B licensing deal to develop targeted cancer treatments using its Pointillist Platform.
Eli Lilly and Co. (NYSE:LLY) short sellers added to their positions, with the latest report following the company’s Q3 2026 earnings release.Short interest rose 3.64% to 7.21 million shares as of the Oct. 30 settlement
The American Academy of Sleep Medicine released a comprehensive report and multiyear roadmap to improve women's sleep health, identifying priority areas including fertility, pregnancy, postpartum health, menopausal transitions, and sleep disorders. The report highlights gaps in research, clinical care, and policy, calling for increased clinical trial representation, research funding, and tailored interventions for women.
The global biotechnology market, valued at USD 2.02 trillion in 2026, is projected to reach USD 6.34 trillion by 2035 at a 13.61% CAGR. Leading biotech companies including Amgen, Gilead, Regeneron, Vertex, and Moderna reported strong Q3 2026 results with revenue growth ranging from 8% to 36%. The sector experienced record dealmaking activity with major acquisitions totaling tens of billions of dollars, driven by patent expiries, strong cash flows, and strategic pipeline expansion in oncology, immunology, and advanced therapies.
RBC Capital analyst Trung Huynh reiterates Eli Lilly (NYSE:LLY) with a Outperform and maintains $1600 price target.
CNBC's Final Trades spotlight Berkshire Hathaway, Cisco and Eli Lilly, citing targets, raised guidance and Lilly's $1.5B Calytrix deal.
Wilserdly is the first and only next-generation all-oral SERD combination to significantly outperform standard endocrine combination in a post-CDK4/6 inhibitor setting in a head-to-head phase III trial (evERA)1In
Ziphius, a biotechnology company specializing in self-amplifying RNA (saRNA), announced the appointment of Antoon Loomans to its Board of Directors. Loomans, a veteran vaccine industry executive with 30 years of experience including 27 years at GSK and recent role at VaxCo (acquired by Eli Lilly for $1.55B), will lead commercial development in the US focusing on strategic partnerships and licensing. The appointment comes as Ziphius advances its lead Chlamydia trachomatis vaccine candidate toward clinical trials and conducts a €30 million fundraising round.
Four sectors are higher and seven are lower in Monday’s regular session, with defensive sectors holding the top three positions. The leaders are clustered rather than widely separated, with the top three staying within a narrow range of one another.
Eli Lilly agrees to buy Calytrix Bio for up to $1.5 billion and presents new Phase 2 and Phase 3 cardiometabolic data at ObesityWeek 2026.
Barclays analyst Emily Field maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $1400 to $1550.
The global anti-obesity drugs market is valued at USD 8.96 billion in 2026 and projected to reach USD 64.96 billion by 2035 at a 24.71% CAGR. Eli Lilly and Novo Nordisk dominate with strong Q3 2026 results, while Pfizer, Roche, and Amgen are investing billions to compete. Key trends include oral GLP-1 formulations, higher efficacy rates (>20% weight loss), and significant manufacturing capacity investments.
XBI and IBB lagged SPY and QQQ as two FDA decisions and fresh Alzheimer's and obesity-drug data put biotech ETFs in focus.
Calytrix Bio, Inc. ("Calytrix"), a company developing precision, disease-modifying therapies for patients living with myeloproliferative neoplasms (MPNs), today announced a definitive agreement for Eli Lilly and
Phase 2 results showed EloraTZP, an investigational combination of eloralintide and tirzepatide, delivered substantial weight loss and A1C improvements in participants with obesity and type 2 diabetesResults from
Invesco Pharmaceuticals ETF (PJP) delivered 36.1% one-year returns with concentrated pharma exposure, significantly outperforming Simplify Health Care ETF (PINK) at 22.7%. PINK offers lower expenses, broader healthcare diversification, and donates profits to breast cancer research, while PJP provides 20+ years of track record but carries sector concentration risk.
An analysis of two leading weight-loss drug manufacturers projects that $10,000 invested equally between Eli Lilly and Novo Nordisk could grow to approximately $11,230 by end of 2027. Eli Lilly is experiencing strong momentum with 39% revenue growth and upcoming retatrutide filing, while Novo Nordisk is bouncing back with oral Wegovy success and the promising CagriSema candidate. Both companies are positioned to benefit from the fast-growing obesity treatment market.
The article compares two healthcare ETFs: VanEck Pharmaceutical ETF (PPH) and iShares Biotechnology ETF (IBB). PPH focuses on 26 large, established drugmakers with lower volatility, higher dividend yield (1.8%), and lower expense ratio (0.36%). IBB offers broader diversification with 243 holdings but higher volatility and minimal dividend yield (0.2%). The author recommends PPH for long-term investors seeking stability and income, particularly given the major pharmaceutical companies' acquisition activity in biotech.
The article compares two healthcare ETFs: State Street's XPH (Pharmaceuticals) and iShares' IBB (Biotechnology). XPH charges lower fees (0.35% vs 0.44%), offers higher dividend yield (0.4% vs 0.2%), and focuses on smaller pharmaceutical companies that are acquisition targets. IBB is significantly larger with $11.3B in assets under management and holds 243 established biotech firms. The analyst recommends XPH for long-term investors due to the pharmaceutical industry's active M&A activity and smaller companies' takeover potential.
News and data on this page is provided by our partnered third-party news and market data provider, with the original publisher credited on each article. All third-party content reflects the views of the original publisher and does not represent the views of MEXC. Price and market data shown on this page are provided by third-party data providers and may be delayed. MEXC offers trading products related to LLY, including RealStocks and Stock Futures.
The content on this page is provided for informational purposes only and does not constitute investment, financial, or trading advice. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of any news or market data shown. Trading U.S. stocks and related products involves significant risk, and prices can move sharply in a short period. Past performance does not guarantee future results. Please conduct your own research and assess your financial situation and risk tolerance before making any investment decisions. MEXC is not liable for any losses arising from the use of this information.